In Western countries, 11C- and 18F-choline PET/CT have been successfully used for restaging prostate cancer in patients with biochemical disease recurrence after undergoing definitive therapy, especially in those with a PSA level >1.0 ng/mL [2, 4, 8]. Here, KLK3 is linked to prostate carcinoma.